[somatropin (rDNA origin) for injection]
For subcutaneous or intramuscular injection
Saizen® [somatropin (rDNA origin) for injection] is a human growth hormone produced by recombinant DNA technology.
Saizen® [somatropin (rDNA origin) for injection] is indicated for the long-term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
Saizen® [somatropin (rDNA origin) for injection] is indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency who meet either of the following two criteria:
Adult Onset: Patients who have growth hormone deficiency, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
Childhood Onset: Patients who were growth hormone deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.
In general, confirmation of the diagnosis of adult growth hormone deficiency in both groups usually requires an appropriate growth hormone stimulation test. However, confirmatory growth hormone stimulation testing may not be required in patients with congenital/genetic growth hormone deficiency or multiple pituitary hormone deficiencies due to organic disease.
Published Studies Related to Saizen (Somatropin)
Cost-effectiveness of somatropin for the treatment of short children born small for gestational age. [2010.06]
BACKGROUND: Short children born small for gestational age (SGA) may be at increased risk for long-term morbidity and reduced health-related quality of life (HRQoL) due to their short stature. Normalization of height in childhood and adolescence is possible in such children via the use of the recombinant human growth hormone somatropin. OBJECTIVE: The aim of this study was to determine whether somatropin was a cost-effective treatment option in short children born SGA... CONCLUSION: In this model, somatropin was a cost-effective treatment option for short children born SGA from the perspective of the UK NHS.
Relative bioavailability of two drug products of somatropin obtained from either the milk of transgenic cows or bacterial culture. 
BACKGROUND: Our objective was to assess the relative bioavailability of the first somatropin produced in transgenic cloned cows that carry the human growth hormone (GH) gene (Biohormon) and somatropin produced in Escherichia coli culture (HHT), the procedure most frequently used for the commercial production of the hormone... CONCLUSION: This study demonstrates that a single dose of Biohormon, the first product with somatropin obtained from milk of transgenic mammals, is bioequivalent to the reference product HHT according to standard criteria. Copyright (c) 2010 S. Karger AG, Basel.
Cost-effectiveness of somatropin for the treatment of short children born small
for gestational age. 
cost-effective treatment option in short children born SGA... CONCLUSION: In this model, somatropin was a cost-effective treatment option for
Effect of the inhaled corticosteroid mometasone on small airway patency in patients with asthma. [2009.05]
The inflammation in asthma involves both the large and the small airways. This study was designed to examine whether mometasone delivered from a dry powder inhaler would improve those parameters thought to reflect patency and obstruction of the small airways (diameter <2 mm)... Mometasone delivered by a dry powder inhaler improved asthma control and pulmonary function in tests reflecting both large and small airways.
Clinical Trials Related to Saizen (Somatropin)
Cool.Clickâ„˘ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-Onset Growth Hormone Deficiency [Completed]
The primary objective is to evaluate the efficacy and safety of two different dose regimens
of r-hGH (Saizen®) in subjects with childhood-onset growth hormone deficiency (COGHD) during
the transition phase from childhood to adulthood.
Extension Study on Safety of Long-Term Growth Hormone Replacement in Adult Patients With Growth Hormone Deficiency [Completed]
To evaluate long-term safety of growth hormone replacement in adult patients with growth
American Norditropin Studies - Registry of Growth Hormone (GH) Patients [Recruiting]
The Norditropin National Registry is a post-marketing registry of patients using Norditropin
A large body of data will be generated to meet the following Registry Objectives:
- To develop a pharmacodynamic model defining the relationship of Norditropin dose to IGF
changes, accounting for effects of known or suspected independent variables such as
age, gender and puberty
- To develop a model defining the relationship of GH dose and IGF exposure to treatment
outcomes, accounting for effects of known or suspected independent variables such as
age, gender and puberty
- To develop a safety model that related GH doses to adverse even occurrence, again
accounting for the effects of known or suspected independent variables
- To determine the relative predictive values of pre-treatment GH stimulation tests and
pre-treatment IGF-I and IGFBP-3 levels
Predictive Markers in GHD and TS Children Treated With SAIZEN® [Completed]
The study aims at identifying the predictive markers after one month of Saizen therapy in
Growth Hormone Deficiency (GHD) and Turner Syndrome children. The study will recruit
approximately 360 children in several countries worldwide. The study lasts for about the
first one month of daily growth hormone treatment. There will be three clinic visits during
the month of the study. There is an initial visit, then a visit before growth hormone
treatment starts and finally a visit at the fourth week of treatment. The study requires two
additional blood tests to a regular Saizen treatment follow-up. One sample is taken before
growth hormone injections start and one additional blood sample is taken at the fourth week
Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects [Recruiting]
Convenience and preference for the new Mark VII pen compared to the current Genotropin pen
will be assessed using a questionaire. it is expected that the new pen will be preferred or
at least no different to the current pen.
Reports of Suspected Saizen (Somatropin) Side Effects
Suicidal Ideation (10),
Angina Pectoris (7),
Urinary Tract Infection (7), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Saizen has an overall score of 8. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
Saizen review by 56 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || adrenal burnout, chronic fatigue & premature agin |
|Dosage & duration:|| || 0.16 mg per injection, 6 nights a week taken 6 nights a week for the period of 6 years|
|Other conditions:|| || insomnia, brain fog, exhaustion|
|Other drugs taken:|| || Armour, T3, hydrocortisone, estradiol, progesterone|
|Benefits:|| || More energy and endurance, much more able to concentrate, skin elasticity improved and noticed overall skin rejuvenation and tightening, sleep improved and wake up feeling more rested, aware of vision improvements and improved libido.|
|Side effects:|| || None. However it did take a long while to see many of the results, perhaps 3 to 6 months for many of the noticeable effects, even though there was some energy improvement noticed within days.|
|Comments:|| || 1 subcutaneous injection of somatropin in abdomen or inner thigh 6 nights a week. |
Page last updated: 2013-02-10